Oct 22, 2003|
Ranbaxy: Delivers a sweet pill
Ranbaxy has announced its 3QFY04 results. On a consolidated basis, the company has posted a topline growth of 14% and a bottomline growth of 25%. For 9mFY04, Ranbaxy has reported a 31% growth in net sales and a 35% rise in net profits. In this context let us make a detailed review of the company’s performance during the quarter.
Results at a glance
|Operating Profit (EBDIT)
|Operating Profit Margin (%)
|Profit before tax
|Profit after Tax but before MI
|Minority Interest (MI)
|Profit after Tax and MI
|Net profit margin (%)
|No. of Shares (m)
|Diluted earnings per share*
During 3QFY04, company’s dosage formulations sales grew by 12%. This growth was fuelled by revenues from Europe, CIS and Africa, which grew by 46% (as a group) as compared to 3QFY03. In Europe, UK (52% growth), Germany (37%), Poland (123%), Russia (103%) and Rest of Europe (98%) are the key markets in which the company operates. Dosage sales in the domestic and Middle East markets grew by 22%. In the domestic market, the company has managed to outperform the industry growth rates in every month of the quarter. The company now commands a leadership position in high growth statin segment.
In the US market, which at US$ 91 m contributes 37% of Ranbaxy’s global sales, growth rates were impacted due to the entry of generics competition for Cefuroxime Axetil, which was one of the key contributors of revenues in the previous quarters. During the quarter under review, Ranbaxy launched three generic products. Moreover, the company is expected to launch three more branded drugs in 4QFY04. However, the strong growth rates achieved by the company in the above markets was pared by a slump in the revenues from the Asia Pacific and Latin American markets. While Ranbaxy’s bulk drug business also witnessed a respectable 11% growth, its allied businesses, which constitutes of animal healthcare, diagnostics and fine chemicals business, has recorded a 5% drop.
|India and Middle East
|Europe, CIS and Africa
|Asia Pacific and Latin America
|Other operating income
Although Ranbaxy’s operating margins saw a marginal decline, reduction in interest cost (in view of the debt restructuring exercise undertaken by the company) and a sharp rise in other income and extra-ordinary income has helped Ranbaxy improve its net margins by 140 basis points. While the rise in the other income was due to higher interest income, extra-ordinary income pertained to settlement compensation income received by the company in relation to a patent dispute.
On the R&D front, Ranbaxy’s BPH molecule, RBX-2258, which is out-licensed to Schwarz Pharma, has completed Phase I study. Meanwhile, the company has also received approval to initiate Phase II study in India on its respiratory compound, RBX-7796. Another key positive for the company is the fact that Bayer has received US-FDA approval to market 1 gm dosage form for Cipro in August ’03. As Bayer is the licensing collaborator of Ranbaxy for Cipro, the approval is likely to trigger a milestone payment for the company. During 3QFY04, Ranbaxy received 7 ANDA approvals taking the total number of approvals in FY04 to 20. In all, the company has until now filed more than 100 ANDAs, with 25 awaiting approval.
Ranbaxy has also entered into a drug discovery and clinical development collaboration with GlaxoSmithKline plc (GSK), covering a wide range of therapeutic areas. As per the terms of the agreement, Ranbaxy will conduct early clinical trial on compounds selected by either Ranbaxy or GSK. Going forward, while GSK will have exclusive worldwide rights for the drug, Ranbaxy will have the right to sell the product in India. However, the detailed financial terms of the agreement have not been disclosed.
At Rs 990, Ranbaxy is trading at a P/E of 24x its annualised 9mFY04 earnings. The strong growth potential in the generics segment combined with its focus on developing a strong NCE and ANDA pipeline augur well for the company going forward. This coupled with the fact that Ranbaxy is likely to successfully meet its long-term target of achieving US$ 1 bn sales by 2005 in this year itself, we remain optimistic about the long-term prospects of the company.
More Views on News
Aug 14, 2017
A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.
Aug 14, 2017
GST impact coupled with price erosion in US leads to lower profits for the quarter.
Aug 8, 2017
Profits plunge due to higher raw material costs.
Jun 23, 2017
Net Profit lower due to exceptional items in the previous year.
May 30, 2017
US markets decline while other geographies grow in the quarter.
More Views on News
Aug 7, 2017
The data tells us quite a different story from the one the government is trying to project.
Aug 4, 2017
The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 7, 2017
Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
TRACK RANBAXY LAB
- Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks